Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 125

1.

Optimizing Transgene Configuration and Protein Fusions to Maximize Dopamine Production for the Gene Therapy of Parkinson's Disease.

Stewart HJ, Ralph GS, Fong-Wong L, Strickland I, McCloskey L, Barnes L, Blount I, Wells O, Truran CJ, Kingsman AJ, Palfi S, Mitrophanous KA.

Hum Gene Ther Clin Dev. 2016 Sep;27(3):100-10. doi: 10.1089/humc.2016.056. Epub 2016 Jul 28.

PMID:
27470285
2.

Retinoic acid receptor beta2 promotes functional regeneration of sensory axons in the spinal cord.

Wong LF, Yip PK, Battaglia A, Grist J, Corcoran J, Maden M, Azzouz M, Kingsman SM, Kingsman AJ, Mazarakis ND, McMahon SB.

Nat Neurosci. 2006 Feb;9(2):243-50. Epub 2005 Dec 25.

PMID:
16388307
3.

Efficient production of germline transgenic chickens using lentiviral vectors.

McGrew MJ, Sherman A, Ellard FM, Lillico SG, Gilhooley HJ, Kingsman AJ, Mitrophanous KA, Sang H.

EMBO Rep. 2004 Jul;5(7):728-33. Epub 2004 Jun 11.

5.

Rabies virus glycoprotein pseudotyping of lentiviral vectors enables retrograde axonal transport and access to the nervous system after peripheral delivery.

Mazarakis ND, Azzouz M, Rohll JB, Ellard FM, Wilkes FJ, Olsen AL, Carter EE, Barber RD, Baban DF, Kingsman SM, Kingsman AJ, O'Malley K, Mitrophanous KA.

Hum Mol Genet. 2001 Sep 15;10(19):2109-21.

PMID:
11590128
6.

Use of intron-disrupted polyadenylation sites to enhance expression and safety of retroviral vectors.

Ismail SI, Rohll JB, Kingsman SM, Kingsman AJ, Uden M.

J Virol. 2001 Jan;75(1):199-204.

7.

Effects of stoichiometry of retroviral components on virus production.

Yap MW, Kingsman SM, Kingsman AJ.

J Gen Virol. 2000 Sep;81(Pt 9):2195-202.

PMID:
10950977
8.

Characterization of the equine infectious anaemia virus S2 protein.

Yoon S, Kingsman SM, Kingsman AJ, Wilson SA, Mitrophanous KA.

J Gen Virol. 2000 Sep;81(Pt 9):2189-94.

PMID:
10950976
9.

Growth factor enhanced retroviral gene transfer to the adult central nervous system.

King LA, Mitrophanous KA, Clark LA, Kim VN, Rohll JB, Kingsman AJ, Colello RJ.

Gene Ther. 2000 Jul;7(13):1103-11.

10.

Analysis of 4070A envelope levels in retroviral preparations and effect on target cell transduction efficiency.

Slingsby JH, Baban D, Sutton J, Esapa M, Price T, Kingsman SM, Kingsman AJ, Slade A.

Hum Gene Ther. 2000 Jul 1;11(10):1439-51.

PMID:
10910141
11.
12.

Possible regulatory function of the Saccharomyces cerevisiae Ty1 retrotransposon core protein.

Roth JF, Kingsman SM, Kingsman AJ, Martin-Rendon E.

Yeast. 2000 Jul;16(10):921-32.

13.

A Rev-independent human immunodeficiency virus type 1 (HIV-1)-based vector that exploits a codon-optimized HIV-1 gag-pol gene.

Kotsopoulou E, Kim VN, Kingsman AJ, Kingsman SM, Mitrophanous KA.

J Virol. 2000 May;74(10):4839-52.

14.

Split-intron retroviral vectors: enhanced expression with improved safety.

Ismail SI, Kingsman SM, Kingsman AJ, Uden M.

J Virol. 2000 Mar;74(5):2365-71.

15.

Yeast Ty retrotransposons assemble into virus-like particles whose T-numbers depend on the C-terminal length of the capsid protein.

AL-Khayat HA, Bhella D, Kenney JM, Roth JF, Kingsman AJ, Martin-Rendon E, Saibil HR.

J Mol Biol. 1999 Sep 10;292(1):65-73.

PMID:
10493857
16.

Cloning and characterization of hIF2, a human homologue of bacterial translation initiation factor 2, and its interaction with HIV-1 matrix.

Wilson SA, Sieiro-Vazquez C, Edwards NJ, Iourin O, Byles ED, Kotsopoulou E, Adamson CS, Kingsman SM, Kingsman AJ, Martin-Rendon E.

Biochem J. 1999 Aug 15;342 ( Pt 1):97-103.

17.

TRIP: a novel double stranded RNA binding protein which interacts with the leucine rich repeat of flightless I.

Wilson SA, Brown EC, Kingsman AJ, Kingsman SM.

Nucleic Acids Res. 1998 Aug 1;26(15):3460-7.

18.

Minimal requirement for a lentivirus vector based on human immunodeficiency virus type 1.

Kim VN, Mitrophanous K, Kingsman SM, Kingsman AJ.

J Virol. 1998 Jan;72(1):811-6.

19.

Cryo-electron microscopy structure of yeast Ty retrotransposon virus-like particles.

Palmer KJ, Tichelaar W, Myers N, Burns NR, Butcher SJ, Kingsman AJ, Fuller SD, Saibil HR.

J Virol. 1997 Sep;71(9):6863-8.

21.

Structure-function studies of the human immunodeficiency virus type 1 matrix protein, p17.

Cannon PM, Matthews S, Clark N, Byles ED, Iourin O, Hockley DJ, Kingsman SM, Kingsman AJ.

J Virol. 1997 May;71(5):3474-83.

22.

Functional dissection of the Moloney murine leukemia virus envelope protein gp70.

Bae Y, Kingsman SM, Kingsman AJ.

J Virol. 1997 Mar;71(3):2092-9.

23.

Identification of proteolytic cleavage sites within the gag-analogue protein of Ty1 virus-like particles.

Martin-Rendon E, Hurd DW, Marfany G, Kingsman SM, Kingsman AJ.

Mol Microbiol. 1996 Dec;22(5):1035-43.

PMID:
8971723
24.

Structural determinants within the subunit protein of Ty1 virus-like particles.

Martin-Rendon E, Marfany G, Wilson S, Ferguson DJ, Kingsman SM, Kingsman AJ.

Mol Microbiol. 1996 Nov;22(4):667-79.

PMID:
8951814
26.

The regulation of human immunodeficiency virus type-1 gene expression.

Kingsman SM, Kingsman AJ.

Eur J Biochem. 1996 Sep 15;240(3):491-507. Review.

27.

The effects of adjuvants on CTL induction by V3:Ty-virus-like particles (V3-VLPs) in mice.

Harris SJ, Woodrow SA, Gearing AJ, Adams SE, Kingsman AJ, Layton GT.

Vaccine. 1996 Jul;14(10):971-6.

PMID:
8873390
28.
29.

Induction of single and dual cytotoxic T-lymphocyte responses to viral proteins in mice using recombinant hybrid Ty-virus-like particles.

Layton GT, Harris SJ, Myhan J, West D, Gotch F, Hill-Perkins M, Cole JS, Meyers N, Woodrow S, French TJ, Adams SE, Kingsman AJ.

Immunology. 1996 Feb;87(2):171-8.

30.
31.

Identification of immunodominant regions and linear B cell epitopes of the gE envelope protein of varicella-zoster virus.

Fowler WJ, Garcia-Valcarcel M, Hill-Perkins MS, Murphy G, Harper DR, Jeffries DJ, Burns NR, Adams SE, Kingsman AJ, Layton GT.

Virology. 1995 Dec 20;214(2):531-40.

32.

Yeast retrotransposon particles as antigen delivery systems.

Kingsman AJ, Burns NR, Layton GT, Adams SE.

Ann N Y Acad Sci. 1995 May 31;754:202-13.

PMID:
7625653
33.

A homologue of the human MSS1 gene, a positive modulator of HIV-1 gene expression, is massively expressed in Xenopus oocytes.

Nacken W, Kingsman AJ, Kingsman SM, Sablitzky F, Sorg C.

Biochim Biophys Acta. 1995 Apr 4;1261(2):293-5.

PMID:
7711076
34.

A transient three-plasmid expression system for the production of high titer retroviral vectors.

Soneoka Y, Cannon PM, Ramsdale EE, Griffiths JC, Romano G, Kingsman SM, Kingsman AJ.

Nucleic Acids Res. 1995 Feb 25;23(4):628-33.

35.

An immunological analysis of Ty1 virus-like particle structure.

Brookman JL, Stott AJ, Cheeseman PJ, Burns NR, Adams SE, Kingsman AJ, Gull K.

Virology. 1995 Feb 20;207(1):59-67.

36.

Promoter control of translation in Xenopus oocytes.

Gunkel N, Braddock M, Thorburn AM, Muckenthaler M, Kingsman AJ, Kingsman SM.

Nucleic Acids Res. 1995 Feb 11;23(3):405-12.

37.

Real-time analysis of the transcriptional regulation of HIV and hCMV promoters in single mammalian cells.

White MR, Masuko M, Amet L, Elliott G, Braddock M, Kingsman AJ, Kingsman SM.

J Cell Sci. 1995 Feb;108 ( Pt 2):441-55.

38.

Requirement for HIV-1 TAR sequences for Tat activation in rodent cells.

Sutton JA, Braddock M, Kingsman AJ, Kingsman SM.

Virology. 1995 Jan 10;206(1):690-4.

39.

Retrovirus and retrotransposon particles as antigen presentation and delivery systems.

Adams SE, Kingsman AJ.

Pharm Biotechnol. 1995;6:769-86. Review. No abstract available.

PMID:
7551247
40.

Intron-less RNA injected into the nucleus of Xenopus oocytes accesses a regulated translation control pathway.

Braddock M, Muckenthaler M, White MR, Thorburn AM, Sommerville J, Kingsman AJ, Kingsman SM.

Nucleic Acids Res. 1994 Dec 11;22(24):5255-64.

41.

Orientation-specific cis complementation by bulge- and loop-mutated human immunodeficiency virus type 1 TAR RNAs.

Braddock M, Powell R, Sutton J, Kingsman AJ, Kingsman SM.

J Virol. 1994 Dec;68(12):8396-400.

42.

Identification of a novel HIV-1 TAR RNA bulge binding protein.

Baker B, Muckenthaler M, Vives E, Blanchard A, Braddock M, Nacken W, Kingsman AJ, Kingsman SM.

Nucleic Acids Res. 1994 Aug 25;22(16):3365-72.

43.

Human immunodeficiency virus type 1 integrase: effect on viral replication of mutations at highly conserved residues.

Cannon PM, Wilson W, Byles E, Kingsman SM, Kingsman AJ.

J Virol. 1994 Aug;68(8):4768-75.

44.

Production and purification of hybrid Ty-VLPs.

Burns NR, Gilmour JE, Kingsman SM, Kingsman AJ, Adams SE.

Mol Biotechnol. 1994 Apr;1(2):137-45.

PMID:
7859157
45.

Expression vectors for the construction of hybrid Ty-VLPs.

Adams SE, Richardson SM, Kingsman SM, Kingsman AJ.

Mol Biotechnol. 1994 Apr;1(2):125-35.

PMID:
7859156
47.

Hybrid Ty virus-like particles.

Adams SE, Burns NR, Layton GT, Kingsman AJ.

Int Rev Immunol. 1994;11(2):133-41. Review.

PMID:
8046274
48.

Immunization of human HIV-seronegative volunteers with recombinant p17/p24:Ty virus-like particles elicits HIV-1 p24-specific cellular and humoral immune responses.

Martin SJ, Vyakarnam A, Cheingsong-Popov R, Callow D, Jones KL, Senior JM, Adams SE, Kingsman AJ, Matear P, Gotch FM, et al.

AIDS. 1993 Oct;7(10):1315-23.

PMID:
8267904
49.

Induction of HIV-specific cytotoxic T lymphocytes in vivo with hybrid HIV-1 V3:Ty-virus-like particles.

Layton GT, Harris SJ, Gearing AJ, Hill-Perkins M, Cole JS, Griffiths JC, Burns NR, Kingsman AJ, Adams SE.

J Immunol. 1993 Jul 15;151(2):1097-107.

PMID:
8335892
50.

Hybrid human immunodeficiency virus Gag particles as an antigen carrier system: induction of cytotoxic T-cell and humoral responses by a Gag:V3 fusion.

Griffiths JC, Harris SJ, Layton GT, Berrie EL, French TJ, Burns NR, Adams SE, Kingsman AJ.

J Virol. 1993 Jun;67(6):3191-8.

Supplemental Content

Loading ...
Support Center